213 related articles for article (PubMed ID: 20071581)
1. Acquisition of complement resistance through incorporation of CD55/decay-accelerating factor into viral particles bearing baculovirus GP64.
Kaname Y; Tani H; Kataoka C; Shiokawa M; Taguwa S; Abe T; Moriishi K; Kinoshita T; Matsuura Y
J Virol; 2010 Apr; 84(7):3210-9. PubMed ID: 20071581
[TBL] [Abstract][Full Text] [Related]
2. Baculovirus GP64-pseudotyped HIV-based lentivirus vectors are stabilized against complement inactivation by codisplay of decay accelerating factor (DAF) or of a GP64-DAF fusion protein.
Guibinga GH; Friedmann T
Mol Ther; 2005 Apr; 11(4):645-51. PubMed ID: 15771967
[TBL] [Abstract][Full Text] [Related]
3. Complement regulatory proteins are incorporated into lentiviral vectors and protect particles against complement inactivation.
Schauber-Plewa C; Simmons A; Tuerk MJ; Pacheco CD; Veres G
Gene Ther; 2005 Feb; 12(3):238-45. PubMed ID: 15550926
[TBL] [Abstract][Full Text] [Related]
4. Lentiviral vectors pseudotyped with baculovirus gp64 efficiently transduce mouse cells in vivo and show tropism restriction against hematopoietic cell types in vitro.
Schauber CA; Tuerk MJ; Pacheco CD; Escarpe PA; Veres G
Gene Ther; 2004 Feb; 11(3):266-75. PubMed ID: 14737086
[TBL] [Abstract][Full Text] [Related]
5. Incorporation of decay-accelerating factor into the baculovirus envelope generates complement-resistant gene transfer vectors.
Hüser A; Rudolph M; Hofmann C
Nat Biotechnol; 2001 May; 19(5):451-5. PubMed ID: 11329015
[TBL] [Abstract][Full Text] [Related]
6. Screening of complement inhibitors: shielded baculoviruses increase the safety and efficacy of gene delivery.
Kaikkonen MU; Maatta AI; Ylä-Herttuala S; Airenne KJ
Mol Ther; 2010 May; 18(5):987-92. PubMed ID: 20179675
[TBL] [Abstract][Full Text] [Related]
7. A GP64-null baculovirus pseudotyped with vesicular stomatitis virus G protein.
Mangor JT; Monsma SA; Johnson MC; Blissard GW
J Virol; 2001 Mar; 75(6):2544-56. PubMed ID: 11222677
[TBL] [Abstract][Full Text] [Related]
8. Baculovirus GP64-mediated entry into mammalian cells.
Kataoka C; Kaname Y; Taguwa S; Abe T; Fukuhara T; Tani H; Moriishi K; Matsuura Y
J Virol; 2012 Mar; 86(5):2610-20. PubMed ID: 22190715
[TBL] [Abstract][Full Text] [Related]
9. Ligand-directed gene targeting to mammalian cells by pseudotype baculoviruses.
Kitagawa Y; Tani H; Limn CK; Matsunaga TM; Moriishi K; Matsuura Y
J Virol; 2005 Mar; 79(6):3639-52. PubMed ID: 15731258
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Combinatory Effects of Plasmodium Circumsporozoite Protein and Complement Regulatory Protein Expression of Recombinant Baculovirus Vectors.
Kawabata C; Kawai Y; Tamura T
Biol Pharm Bull; 2021; 44(2):219-224. PubMed ID: 33518673
[TBL] [Abstract][Full Text] [Related]
11. Virion-associated complement regulator CD55 is more potent than CD46 in mediating resistance of mumps virus and vesicular stomatitis virus to neutralization.
Johnson JB; Lyles DS; Alexander-Miller MA; Parks GD
J Virol; 2012 Sep; 86(18):9929-40. PubMed ID: 22761385
[TBL] [Abstract][Full Text] [Related]
12. Protection of Baculovirus Vectors Expressing Complement Regulatory Proteins against Serum Complement Attack.
Kawai Y; Kawabata C; Sakaguchi M; Tamura T
Biol Pharm Bull; 2018; 41(10):1600-1605. PubMed ID: 30270330
[TBL] [Abstract][Full Text] [Related]
13. Retroviruses prepared from human DAF expressing murine packaging cells acquire resistance against human serum.
Hiasa A; Watanabe M; Okada H; Ikenaka K; Fujita T; Yoshimatsu T; Kanematsu T; Shiku H
Int J Oncol; 1999 Jun; 14(6):1091-6. PubMed ID: 10339663
[TBL] [Abstract][Full Text] [Related]
14. Pseudotyping Autographa californica multicapsid nucleopolyhedrovirus (AcMNPV): F proteins from group II NPVs are functionally analogous to AcMNPV GP64.
Lung O; Westenberg M; Vlak JM; Zuidema D; Blissard GW
J Virol; 2002 Jun; 76(11):5729-36. PubMed ID: 11992001
[TBL] [Abstract][Full Text] [Related]
15. Delta-short consensus repeat 4-decay accelerating factor (DAF: CD55) inhibits complement-mediated cytolysis but not NK cell-mediated cytolysis.
Miyagawa S; Kubo T; Matsunami K; Kusama T; Beppu K; Nozaki H; Moritan T; Ahn C; Kim JY; Fukuta D; Shirakura R
J Immunol; 2004 Sep; 173(6):3945-52. PubMed ID: 15356143
[TBL] [Abstract][Full Text] [Related]
16. Production of GP64-free virus-like particles from baculovirus-infected insect cells.
Chaves LCS; Ribeiro BM; Blissard GW
J Gen Virol; 2018 Feb; 99(2):265-274. PubMed ID: 29300162
[TBL] [Abstract][Full Text] [Related]
17. Preparation of pseudotyped lentiviral vectors resistant to inactivation by serum complement.
Guibinga GH; Friedmann T
Cold Spring Harb Protoc; 2010 Jul; 2010(7):pdb.prot5420. PubMed ID: 20647353
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo gene delivery by recombinant baculoviruses.
Tani H; Limn CK; Yap CC; Onishi M; Nozaki M; Nishimune Y; Okahashi N; Kitagawa Y; Watanabe R; Mochizuki R; Moriishi K; Matsuura Y
J Virol; 2003 Sep; 77(18):9799-808. PubMed ID: 12941888
[TBL] [Abstract][Full Text] [Related]
19. Large-scale production of pseudotyped lentiviral vectors using baculovirus GP64.
Kumar M; Bradow BP; Zimmerberg J
Hum Gene Ther; 2003 Jan; 14(1):67-77. PubMed ID: 12573060
[TBL] [Abstract][Full Text] [Related]
20. Improving Baculovirus Transduction of Mammalian Cells by Incorporation of Thogotovirus Glycoproteins.
Hu L; Li Y; Deng F; Hu Z; Wang H; Wang M
Virol Sin; 2019 Aug; 34(4):454-466. PubMed ID: 31201733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
